Incyte prepares oncology, dermatology products
April 28, 2020Incyte last week named the new Canada Biosciences head, announcing establishing key development and commercialization capabilities in preparation for potential launches of multiple products in the near future.
Jenifer Antonacci, Sr. Director, U.S. Public Affairs told Pharmaceutical Daily in an email that Incyte has multiple opportunities to launch new products and new indications globally in the next several years, including pemigatinib, tafasitamab, and parsaclisib in oncology, and ruxolitinib cream in dermatology.
“We are working to define our regulatory strategy for these late-stage products in Canada, as well as for our early-stage portfolio, and look forward to working closely with Health Canada on the submission and evaluation of regulatory filings in the future,” Antonacci told Pharmaceutical Daily.